– USA, OH – Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem for critical care indications, today announced the appointment of current Director Jane Wasman, JD, as Chair of its Board of Directors, effective September 28, 2023
Ms. Wasman has served as a Director of the Company since November 2020, currently serving as Chair of the Audit Committee.
“We are delighted that Jane will now be chairing Athersys’ board. She brings a wealth of expertise in strategic, operational, business development and corporate governance matters to Athersys. With Athersys’ multiple late-stage programs, including our most advanced Phase 3 MASTERS-2 trial evaluating MultiStem in treating ischemic stroke, Jane’s background in the life sciences industry is a valued resource as we progress towards completing our pivotal study,” said CEO, Dan Camardo.
About
Ms. Wasman is the Founder and President of JWasman Advisors, a consulting firm focused on strategic, operational, and corporate governance matters for biopharma and life sciences organizations. She also is chair of the board of directors of Sellas Life Sciences (Nasdaq: SLS) and a member of the board of directors of Rigel Pharmaceuticals (Nasdaq: RIGL). Additionally, she co-founded and co-chairs the NY Hub of BioDirector, an organization supporting board effectiveness and diversity. Previously, she served as President, International, and General Counsel at Acorda Therapeutics, where she was responsible for global strategic development, leading long-range planning and development in addition to international expansion, as well as the legal and compliance functions. Before joining Acorda, Ms. Wasman held various leadership positions at Schering-Plough Corporation, including VP and Associate General Counsel.
“On behalf of the Athersys Board of Directors and the company’s employees, I am honored to assume the responsibilities of Board Chair and to help guide our various initiatives to drive shareholder value,” said Jane Wasman.
Ms. Wasman graduated magna cum laude from Princeton University and earned her J.D. from Harvard Law School.
About Athersys
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Athersys is developing its MultiStem cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization.
SOURCE: https://www.athersys.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.